Ryan Scott

Articles

Trastuzumab Deruxtecan Continues to Reshape HER2+ Breast Cancer Treatment Paradigm

October 17th 2023

Lubna Chaudhary, MD, MS, discusses how findings from the various DESTINY-Breast trials affected the treatment landscape in HER2-positive breast cancer, the trials’ impact on the treatment arena, the evolving treatment landscape for patients with HER2-positive breast cancer, and the importance of staying updated on new drugs and clinical trials.

Emerging Therapies Underscore Need for Genomic Testing in HR+/HER2– Breast Cancer

October 16th 2023

Kari Wisinski, MD, highlights the use of oral selective estrogen receptor degraders and CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive/HER2-negative breast cancer, the growing role of antibody-drug conjugates across the breast cancer spectrum, and ongoing research taking place at Carbone Cancer Center.

Infection Risk Increases With Longer Surgical Duration in Lower Extremity Bone Tumors

October 15th 2023

R. Lor Randall, MD discusses the primary results of the PARITY study and their implications for the use of antibiotics for patients with lower extremity bone tumors undergoing surgery and highlighted the findings from the secondary analysis of the study on the effect of surgical duration on risk of infection

Ceralasertib/Durvalumab Demonstrates Efficacy in RAS-Mutant Advanced NSCLC Post Immune Checkpoint Blockade

October 14th 2023

Treatment with the combination of ceralasertib and durvalumab elicited preliminary efficacy signals in patients with advanced non–small cell lung cancer with and without RAS mutations who received prior treatment with immune checkpoint blockade.

NVL-655 Elicits Preliminary Activity, Safety in Heavily Pretreated, ALK+ Advanced NSCLC

October 13th 2023

Treatment with the novel, ALK-selective TKI NVL-655 generated responses and was well tolerated in heavily pretreated patients with ALK-positive, advanced non–small cell lung cancer.

Ongoing Research Could Add to Atezolizumab/Bevacizumab Backbone in First-Line Treatment of Unresectable HCC

October 12th 2023

Daneng Li, MD, discusses the current options available for the frontline treatment of patients with unresectable HCC, factors to consider when selecting a treatment regimen for this patient population, how Child-Pugh B score and bleeding could affect these decisions, and ongoing research using the atezolizumab/bevacizumab backbone in novel combinations.

FDA Grants Fast Track Designation to SurVaxM in Newly Diagnosed Glioblastoma

October 12th 2023

The FDA has granted fast track designation to the investigational vaccine SurVaxM for the treatment of patients with newly diagnosed glioblastoma.

Strategies to Improve Manufacturing Time, Mitigate Toxicities of CAR T-Cell Therapy Remain a Focus in R/R LBCL

October 12th 2023

Hemant S. Murthy, MD, emphasizes the importance of an accelerated manufacturing process for CAR T-cell therapy, discusses the use of CAR T-cell therapy in older and frail patients, and highlights toxicity management strategies that have implemented and are under evaluation for patients receiving CAR T-cell therapy.

FDA Awards Orphan Drug Designation to SLS009 in AML

October 11th 2023

The FDA has granted an orphan drug designation to SLS009 for the treatment of patients with acute myeloid leukemia.

Elranatamab Represents Another Off-the-Shelf Option for Heavily Pretreated R/R Myeloma

October 6th 2023

Ajay Kumar Nooka, MD, MPH, FACP, highlights the significance of the FDA approval of elranatamab for select patients with relapsed/refractory multiple myeloma and sheds light on the agent’s role in the expanding field of T cell–redirecting therapies approved for the treatment of this patient population.

Reduced-Dose and Partial-Breast Radiotherapy Sustain Long-Term Safety and Efficacy in Early-Stage Breast Cancer

October 4th 2023

Treatment with reduced-dose or partial-breast radiotherapy sustained long-term safety and elicited similar rates of ipsilateral breast tumor relapse compared with whole-breast radiotherapy in patients with early-stage breast cancer.

FDA Awards Orphan Drug Designation to FG001 in High-Grade Glioma

October 4th 2023

The FDA has granted an orphan drug designation to FG001 as an optical imaging agent for the visualization of malignant tissue during surgery for patients with high-grade glioma.

NT219 Plus Cetuximab Elicits Responses, Demonstrates Tolerability in Recurrent or Metastatic HNSCC

October 3rd 2023

Second-line treatment with NT219 alone and in combination with cetuximab demonstrated safety and tolerability, and the combination produced confirmed partial responses in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Evorpacept Plus Trastuzumab/Ramucirumab/Paclitaxel Improves ORR in Pretreated, Advanced HER2+ Gastric/GEJ Cancer

October 3rd 2023

Second- or third-line treatment with the CD47 blocker evorpacept in combination with trastuzumab, ramucirumab, and paclitaxel improved responses vs trastuzumab/ramucirumab/paclitaxel alone in patients with HER2-positive, advanced gastric and gastroesophageal junction cancer.

FDA Grants Fast Track Designation to AVB-001 for R/R Platinum-Resistant Ovarian Cancer

October 2nd 2023

The FDA has granted fast track designation to AVB-001 for the treatment of adult patients with relapsed/refractory, platinum-resistant, high-grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.

FDA Awards Orphan Drug Designation to Alisertib in ES-SCLC

October 1st 2023

The FDA has granted an orphan drug designation to alisertib (MLN8237) for the treatment of patients with extensive-stage small cell lung cancer.

NXC-201 Demonstrates Feasibility of BCMA-Directed CAR T-Cell Therapy in Relapsed/Refractory AL Amyloidosis

September 30th 2023

The novel anti-BCMA CAR T-cell therapy NXC-201 displayed safety and elicited hematologic and organ responses in patients with relapsed/refractory amyloid light chain amyloidosis, including frail patients.

Zolbetuximab Could Alter Frontline Treatment Paradigm for CLDN18.2+ Gastric/GEJ Cancer

September 28th 2023

Andrew Ko, MD, FASCO, highlights what the potential approval of zolbetuximab could mean for the first-line treatment paradigm for patients with CLDN18.2-positive gastric/gastroesophageal junction adenocarcinoma and detailed other ongoing research in the gastrointestinal cancer space.

Sotorasib Plus Carboplatin/Pemetrexed Displays Activity, Safety in KRAS G12C+ NSCLC

September 28th 2023

Treatment with the combination of sotorasib carboplatin, and pemetrexed produced responses and demonstrated safety in patients with KRAS G12C–mutated, advanced non–small cell lung cancer, according to data from the phase 1/2 CodeBreaK 101 trial.

Deeper Understanding of immune System Could Advance Treatment Options in Lymphoma

September 26th 2023

Stephen M. Ansell, MD, PhD, discusses the successes and challenges of utilizing immune therapy across the landscape of hematologic malignancies, the importance of increasing the understanding of how the immune system functions in patients with lymphoma, and ongoing research of immune therapy for this patient population.